Tirzepatide is a once-weekly injectable peptide that activates both GLP-1 and GIP receptors simultaneously, producing greater weight loss and blood sugar control than any single-receptor agent currently approved.
What it does
Tirzepatide works by activating two hormone receptors at once. The first is the GLP-1 receptor (glucagon-like peptide-1 receptor), which suppresses appetite, triggers insulin release in proportion to blood sugar levels, blunts glucagon (the hormone that raises blood sugar), and slows stomach emptying so you feel full longer. These are the same effects semaglutide produces. The second is the GIP receptor (glucose-dependent insulinotropic polypeptide receptor), which amplifies insulin secretion beyond what GLP-1 alone can achieve and appears to drive remodeling of adipose tissue (body fat distribution) while improving how the body handles dietary fat Karlie 2026.
The molecule itself is a synthetic 39-amino acid chain with a C20 fatty acid tail attached. That tail lets tirzepatide bind loosely to albumin (a protein that circulates in the blood), which slows its clearance and gives it a half-life of roughly five days — long enough for once-weekly dosing Karlie 2026. FDA approved it as Mounjaro for type 2 diabetes and as Zepbound for obesity.
The clinical significance of adding GIP agonism to GLP-1 agonism appears to be additive or synergistic rather than redundant. Head-to-head data and cross-trial comparisons consistently show tirzepatide outperforming GLP-1-only agents on both weight and glycemic endpoints Karlie 2026.
What the evidence shows
Weight loss (obesity) Strong Phase 3 human trial data (~2,500 participants in SURMOUNT-1 alone)
The SURMOUNT-1 trial found that participants taking 15 mg tirzepatide weekly lost an average of 22.5% of body weight over 72 weeks — a figure that exceeded the 14.9% seen in semaglutide's STEP 1 trial, though these were separate studies with different populations Karlie 2026. Real-world and telehealth data have begun to emerge as well; one virtual-care cohort reported meaningful weight reduction with high treatment adherence using a structured tirzepatide protocol Jessica 2026. Discontinuation rates in at least one observational dataset were low, suggesting tolerability holds up outside controlled trial conditions Takahiro 2025.
Type 2 diabetes (glycemic control) Strong Phase 3 human trial data across multiple SURPASS trials
Across the SURPASS trial program, tirzepatide produced HbA1c reductions of 2.0–2.6 percentage points — exceeding comparator arms including semaglutide Karlie 2026. Case reports have documented utility in atypical subtypes such as cystic fibrosis-related diabetes Yashwanth 2025, and head-to-head trials against next-generation agents are underway NCT06221969.
Diabetic kidney disease Early mechanistic and animal data; limited human evidence
Rodent research suggests tirzepatide may protect kidney function in diabetes partly by modulating the gut microbiota (the ecosystem of bacteria in the digestive tract), which in turn reduces systemic inflammation that damages kidney tissue Jun 2025. Human data in this area remain limited, and kidney protection is not a current approved indication.
Inflammatory bowel disease with metabolic comorbidity Observational and trial-level interest; no completed RCTs specific to this indication
GLP-1/GIP receptor agonists as a class show a signal toward reduced biliary complications in type 2 diabetes patients with inflammatory bowel disease Ibrahim 2025. A Phase 3b trial is actively studying tirzepatide combined with the IBD drug mirikizumab in overweight patients with ulcerative colitis NCT06937086. No completed efficacy data specific to this use exist yet.
How it's used
In clinical trials and approved prescribing practice, tirzepatide is injected subcutaneously (under the skin, typically in the abdomen, thigh, or upper arm) once weekly, on the same day each week. The standard escalation schedule starts at 2.5 mg weekly for four weeks to allow GI tolerance to develop, then steps up in 2.5 mg increments every four weeks toward maintenance doses of 5, 10, or 15 mg weekly. The 15 mg dose produced the largest weight loss in SURMOUNT-1. Half-life is approximately five days, so plasma levels are relatively stable week to week at steady state. Self-reported and telehealth-based protocols generally mirror this escalation structure Jessica 2026. Tirzepatide should be taken on a consistent weekly schedule; if a dose is missed by fewer than four days, it can be taken as soon as possible.
Side effects and safety
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal discomfort. These are most pronounced during dose escalation and tend to diminish over time — a pattern observed in both trials and real-world cohorts Takahiro 2025. Severe but rarer risks include pancreatitis (inflammation of the pancreas) and, based on rodent carcinogenicity studies, a boxed warning for thyroid C-cell tumors (medullary thyroid carcinoma, or MTC). This warning drives the absolute contraindications: personal or family history of MTC, and MEN-2 (multiple endocrine neoplasia type 2, a hereditary tumor syndrome). No MTC cases have been confirmed in human tirzepatide trials to date, but the warning stands. Severe hypoglycemia (dangerously low blood sugar) is a risk primarily when tirzepatide is combined with insulin or sulfonylureas. One case report flagged possible new-onset atrial fibrillation associated with tirzepatide use, though causation is unestablished Akhtar 2025. Euglycemic diabetic ketoacidosis (a metabolic crisis where ketones build up even without high blood sugar) has been reported, including in an online-prescribing context, underscoring the importance of appropriate medical oversight Thibagaran 2025. For patients using cannabis concurrently, intractable vomiting has been reported and may complicate GI symptom assessment Peter 2025. Long-term safety data beyond the trial durations (~72–88 weeks) are still accumulating. Perioperative use requires specific protocols given effects on gastric emptying Rodrigo 2025.
Bottom line
Tirzepatide has the strongest efficacy data of any approved obesity or diabetes injectable at this writing — the 22.5% average weight loss in SURMOUNT-1 and 2.0–2.6% HbA1c reductions across SURPASS trials are backed by large, well-designed Phase 3 trials. The side effect profile is manageable for most people but real, and the boxed warning for thyroid tumors means it is not appropriate for anyone with a personal or family history of medullary thyroid cancer or MEN-2. It is a prescription drug in the United States with established regulatory oversight — not a research compound — so the relevant question is fit and access, not whether the evidence supports its use.